In silico Pharmacokinetic, Bioactivity and Toxicity Evaluation of Some Selected Anti-Diabetic Agents
Abstract
Diabetes mellitus is among the most common chronic metabolic disorders worldwide and is characterized by persistently high blood glucose levels resulting from insufficient insulin secretion, insulin resistance, or a combination of both. The primary goals of diabetes management are to maintain optimal glycemic control, reduce symptoms, and prevent long-term complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy. Although several anti-diabetic therapies are currently available, many are associated with limitations, including hypoglycemia, weight gain, gastrointestinal discomfort, and concerns regarding long-term safety. Therefore, evaluating the drug-likeness, pharmacokinetic behavior, biological activity, and toxicity potential of existing anti-diabetic drugs is crucial to support the development of safer and more effective alternatives. In this study, in silico computational approaches were used to analyse the pharmacokinetic profiles, bioactivity scores, and toxicity risks of six commonly prescribed anti- diabetic agents: metformin, sit gliptin, pioglitazone, empagliflozin, dapagliflozin, and glimepiride. Key physicochemical parameters such as molecular weight, logP, topological polar surface area (TPSA), hydrogen bond donors and acceptors, rotatable bonds, and predicted absorption were calculated using Mo inspiration Cheminformatics tools and assessed according to Lipinski’s rule of five. Bioactivity was evaluated across major biological…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.